HOME

UNLOCKING THE EFFICACY OF IMMUNO-ONCOLOGY

Mission: IOME Bio aims to harness unique mechanistic insights to overcome resistance to checkpoint inhibitors and deliver meaningful benefits for cancer patients

SCIENCE

IOME Bio builds on foundational insights and IP from world-renowned immuno-oncology researchers, and has an exclusive option to licence new IP arising from ongoing sponsored research at Harvard

ABOUT US

We are a venture-backed Harvard spin-off pursuing novel immuno-oncology targets with first-in-class antibodies

Our foundational science was discovered by Arlene Sharpe and Dennis Kasper at Harvard, and Gordon Freeman at the Dana-Farber Cancer Institute

We are addressing resistance to PD-1 blockade through proprietary mechanistic insights

We are centrally located in the beautiful city of Strasbourg, embedded in a vibrant health innovation ecosystem.

CONTACT

Currently, the form is not active, Please come back soon

OUR LATEST NEWS

New Offices and Labs

On September 13 IOME Bio organized the inauguration of its laboratories now established within the Paul Strauss Center, in the heart of Strasbourg. This was an opportunity for the Managing Director, Sarah Holland, to thank all the partners in the … Read More

Featured Post

The IOME Bio team will meet potential investors and partners at the following conferences

• RESI – Boston, Sep 21-23
• SACHS Associates – Basel, Sep 21-22
• BIO EUROPE – Leipzig, Oct 24-26
• J.P. Morgan – San Francisco, Jan 2023
Read More

Featured Post